An abstract black and white background with lots of dots

Global Value Dossier

Global Value Dossiers Built for Modern Market Access. Supporting global evidence strategies with a connected, living Global Value Dossier.

Instead of rebuilding static documents every time evidence changes, ATLAS helps Market Access, HEOR, Medical Affairs, and cross-functional launch teams maintain a continuously evolving Global Value Dossier that connects evidence, value messages, and launch activities in one platform.

Traditional Global Value Dossiers have become increasingly difficult to maintain—not because the concept is outdated, but because today's evidence landscape evolves continuously.

Evidence grows

HTA expectations change

Value messages mature

Affiliates require localization

Instead of treating the Global Value Dossier as a document that must be recreated every few months, ATLAS helps organizations manage the underlying evidence ecosystem that keeps the dossier continuously current.

What is a Global Value Dossier?

A Global Value Dossier (GVD) is a comprehensive evidence package that communicates the clinical, economic, humanistic, and strategic value of a healthcare product. It provides global teams with a consistent foundation that local affiliates can adapt for reimbursement submissions, payer engagement, and Health Technology Assessment (HTA) activities across markets

Why Global Value Dossiers Matter?

A well-developed Global Value Dossier enables organizations to:

Align global Market Access strategy

Support affiliate reimbursement activities

Accelerate local adaptation

Maintain consistent value messaging

Improve cross-functional collaboration

Prepare for HTA submissions

Reduce duplication across markets

As evidence packages become larger and more complex, the Global Value Dossier increasingly serves as a strategic knowledge asset rather than simply a launch document.

Common Challenges with Traditional Global Value Dossiers

Static Documents

PDFs become outdated as soon as new evidence becomes available.

Disconnected Evidence

Clinical studies, HEOR models, publications, value messages, and launch activities often exist in separate systems.

Duplicate Work

Evidence is copied into multiple presentations, dossiers, and country adaptations.

Limited Traceability

Understanding where a value claim originated—or whether it is still supported by the latest evidence—can require extensive manual review.

Difficult Localization

Local affiliates spend valuable time finding supporting evidence and adapting content for country-specific requirements.

Static Documents

PDFs become outdated as soon as new evidence becomes available.

Duplicate Work

Evidence is copied into multiple presentations, dossiers, and country adaptations.

Difficult Localization

Local affiliates spend valuable time finding supporting evidence and adapting content for country-specific requirements.

Disconnected Evidence

Clinical studies, HEOR models, publications, value messages, and launch activities often exist in separate systems.

Limited Traceability

Understanding where a value claim originated—or whether it is still supported by the latest evidence—can require extensive manual review.

Static Documents

PDFs become outdated as soon as new evidence becomes available.

Duplicate Work

Evidence is copied into multiple presentations, dossiers, and country adaptations.

Difficult Localization

Local affiliates spend valuable time finding supporting evidence and adapting content for country-specific requirements.

Disconnected Evidence

Clinical studies, HEOR models, publications, value messages, and launch activities often exist in separate systems.

Limited Traceability

Understanding where a value claim originated—or whether it is still supported by the latest evidence—can require extensive manual review.

These challenges are consistently recognized across industry guidance on value dossier development, particularly as evidence bases expand and launch timelines accelerate.

Introducing the Living Global Value Dossier

Rather than viewing the Global Value Dossier as a document, ATLAS treats it as a connected knowledge system.

Evidence updates automatically strengthen linked value messages

New publications become immediately available

Evidence gaps remain visible

Supporting activities stay linked

Every value message maintains traceability back to its supporting evidence

Users can provide real-time feedback through comments

The result is a Living Global Value Dossier that evolves alongside your product throughout development, launch, and post-launch evidence generation.

How ATLAS Supports Global Value Dossier Development

Instead of writing the dossier from scratch, teams build it naturally through everyday evidence planning activities.

Connected Evidence Repository

Maintain a centralized evidence library with structured metadata, linked publications, endpoints, outcomes, and key evidence statements.

Value Message Management

Connect every value message directly to supporting evidence while maintaining full traceability.

Integrated Evidence Planning

Identify evidence gaps early and link planned evidence-generation activities to the value story.

Affiliate Adaptation

Provide local teams with access to the latest approved evidence and supporting materials without recreating content.

AI-Assisted Knowledge Management

Use AI to identify key evidence, summarize publications, and help maintain evidence consistency across the product lifecycle.

A Biopharma-Specialist Software Innovator

Arysana develops digital solutions for biopharma evidence generation and dissemination workflows

AI Position Statement

A Biopharma-Specialist Software Innovator

Arysana develops digital solutions for biopharma evidence generation and dissemination workflows

AI Position Statement

A Biopharma-Specialist Software Innovator

Arysana develops digital solutions for biopharma evidence generation and dissemination workflows

AI Position Statement